Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M Series A (Mar 2026) at $2B+ valuation led by AON Consulting. 91%+ medication adherence. GLP-1 benefits platform for employers. Linda Yaccarino CEO.
eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.